Veröffentlichungen

Die Kommunikation von Forschungsergebnissen ist entscheidend. Diese zeigt sich an dem hohen Niveau von Veröffentlichungen in einflussreichen Zeitschriften sowie an Postern und der Teilnahme an den weltweit wichtigsten Kongressen, speziell im Bereich der Neurowissenschaften.

Im Folgenden finden Sie einige Beispiele für Veröffentlichungen, die von Wissenschaftlern von BIAL verfasst oder mitverfasst wurden.

Tabs

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, et al.

Published: Epilepsia [Internet]. 2018;59(2):479–91.

Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, Tolerability and Efficacy of Eslicarbazepine

Published: Drugs Aging [Internet]. 2018;null–null.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.

Published: Epilepsy & behavior : E&B [Internet]. 2018;81:1–11.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study.

Christian Elger.

Published: Epilepsia. 2009;50(3):454–63.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

E. Ben-Menachem.

Published: Epilepsy Res Suppl. 2010;89(2-3):278–85.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

A. Gil-Nagel.

Published: Acta Neurol Scand. 2009;120(5):281–7.

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.

Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al..

Published: Epilepsia [Internet]. 2015;56(2):244–53.

Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Published: Eur J Neurol [Internet]. 2019;null–null.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al.

Published: Neurology [Internet]. 2018;90(21):e1849–e1857.

Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ.

Published: Lancet Neurol. 2016;15(2):154–65.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, et al.

Published: Eur J Clin Pharmacol [Internet]. 2014;70(9):1059–71.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al.

Published: JAMA Neurol [Internet]. 2017;74(2):197–206.

Pre-Clinical

.

Effect of zamicastat in chronic treatment on right ventricle pressure overload in the rat monocrotaline lung injury model of pulmonary hypertension

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Published: Hypertension. 2016;68(Suppl. 1: AP238).

Effect of Chronic Treatment With Zamicastat on Right Ventricle Pressure Overload in the Rat Monocrotaline Lung Injury Model of Pulmonary Hypertension.

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Published: The FASEB Journal. 2017;31(1 Supplement 1070.7).

Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension.

Moura, E., Costa, C., Igreja B., Pires, et al.

Published: European Respiratory Society Meeting. 2020.

The Dopamine Beta-Hydroxylase Inhibitor Zamicastat Improves Survival in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension.

Bonifacio M.J., Moura E., Sousa F., Igreja B., Pires N., Soares-da-Silva P.

Published: J Respir Crit Care Med. 2020;(201:A2088).

Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension.

Pires N., Igreja B., Magalhães L., Bonifácio M.J., Chevalier E., Soares-da-Silva P.

Published: Pulmonary Hypertension. 2020.

BIA 5-1058 is a new noncompetitive dopamine-β-hydroxylase inhibitor.

Bonifacio M.J., Sousa F., Igreja B., Loureiro A.I., Wright L.C., Soares-da-Silva P.

Published: Proceedings of the British Pharmacological Society. 2012.

In vitro Species Different Metabolism and CYP Phenotyping of Zamicastast.

Loureiro A.I., Rebouta J., Bonifácio M.J., Soares-da-Silva P.

Published: FASEB J. 2020;34(S1):1–1.

Clinical

.

A Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Zamicastat, in Healthy Male Volunteers.

Magalhães L., Rocha F., Falcão A., Gama H., Soares-da-Silva P.

Published: American Journal of Respiratory and Critical Care Medicine. 2020;201:A3816.

A Randomized, Double-Blind, Placebo-Controlled and Open-Label, Active-Controlled, 4-Period Crossover Trial to Evaluate the Effect of Zamicastat on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions.

Gama H., Magalhães L., Santos A., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine. 2020;201:A3815.

Drug-drug interaction study between zamicastat and bosentan in healthy subjects.

Guimarães A., Santos A., Ferreira J., Magalhães L., Gama H., Soares da Silva P.

Chest. 2020;157(6):A382.

Drug-drug interaction study between zamicastat and sildenafil in healthy subjects.

Santos A., Ferreira J., Gama H., Magalhães P. Soares -da-Silva P.

European Respiratory Journal 2020 56: 1458.

Drug-drug interaction study between zamicastat and treprostinil in healthy subjects.

Magalhães L., Guimarães A.M.R., Gana H., Magalhães P., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine 2021;203:A3615.

×

Sie verlassen die Website von BIAL.

BIAL übernimmt die Verantwortung für die Inhalte seiner Website. Durch Anklicken von "Weiter" gelangen Sie auf eine externe Website, die außerhalb des Verantwortungsbereichs von BIAL liegt.

ABBRECHEN FORTSETZEN